Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126829941 | 12682994 | 1 | I | 20160811 | 20160825 | 20160825 | EXP | US-CIPLA LTD.-2016US17613 | CIPLA | MICHAEL S IRWIG. SAFETY CONCERNS REGARDING 5A REDUCTASE INHIBITORS FOR THE TREATMENT OF ANDROGENETIC ALOPECIA. CURR OPIN ENDOCRINOLDIABETES OBES. 2015;22:248 TO 253 | 0.00 | Y | 0.00000 | 20160825 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126829941 | 12682994 | 1 | PS | FINASTERIDE. | FINASTERIDE | 1 | Unknown | UNK | U | 0 |
Indications of drugs used
| no results found |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126829941 | 12682994 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126829941 | 12682994 | Depressed mood | |
| 126829941 | 12682994 | Disturbance in attention | |
| 126829941 | 12682994 | Erectile dysfunction | |
| 126829941 | 12682994 | Libido decreased | |
| 126829941 | 12682994 | Testicular pain |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |